SPRAVATO™ (esketamine)

LENGTH OF AUTHORIZATION: 3 MONTHS

INITIAL THERAPY REVIEW CRITERIA:
- Patient is ≥ 18 years old.
- Diagnosis of major depressive disorder without psychotic features.
- Documented trial and failure of two preferred oral antidepressants in different therapeutic classes (e.g. SSRIs, SNRIs, TCAs) taken at an adequate dose for a minimum of four (4) weeks.
- Patient must have been compliant with the two preferred oral antidepressant regimens.
- Patient is using Spravato in conjunction with an oral antidepressant.

CONTINUATION OF THERAPY REVIEW CRITERIA:
- Patient is using Spravato in conjunction with an oral antidepressant.
- Documentation submitted indicating the patient clinically benefited from the therapy.

DOSING AND ADMINISTRATION:
Induction Phase:
Weeks 1-4: Administer twice per week 56mg or 84mg intranasally.

Maintenance Phase:
Weeks 5-8: Administer once weekly 56mg or 84mg intranasally.
Weeks 9 and thereafter: Administer every 2 weeks or once weekly 56mg or 84mg intranasally.

The nasal spray delivers 28 mg per device. Use 2 devices for a 56 mg dose or 3 devices for an 84 mg dose, with a 5-minute rest between use of each device.

SPRAVATO must be administered under the direct supervision of a healthcare professional only in a setting with adequate patient monitoring facilities. Monitor patients for at least two hours after administration.

Spravato is only available through a restricted program called the Spravato (esketamine) REMS due to serious risk of sedation, dissociation, and abuse/misuse.